Some sales projections from presentation to American Heart Association at Orlando, excerpts from DJNews:
"Butler said the cost of the drug is $200 a day per patient, and added that his sales estimates should be considered conservative. Butler estimates sales in 1998 at being $38 million for the HIT indication, which could grow to over $100 million by 2000. For acute myocardial infarction, the sales figures in 1999 are $22 million, which could grow to $45 million 2000. For stroke, the sales are not likely to begin until 2001. He believes those sales will be $100 million. Overall, potential peak sales for the drug are believed to be $38 million, moving to to roughly $150 million by 2000, and to $480 million in 2005."
---------
Nothing earth-shaking in the rest of the article. Still looking at Spring 98 for approval of Novastan. While these numbers are nice, we still need success on the endothelin antagonist and/or asthma med testing to send this stock into orbit. '98 will be the show-and-tell year, IMO. |
